Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00037791 | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | PHASE3 | COMPLETED | 180 | — | — | Dec 1, 1999 | Sep 1, 2002 | Nov 9, 2006 | 9 | United States, Argentina +1 |
| Name | Type | Description |
|---|---|---|
| (PN-152,243)/PN-196,444 | DRUG | - |
Inclusion Criteria: * Patients must have solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support Exclusion Criteria: * Patients must not have active bleeding (exclusions do apply) or history of platelet disorder